BioTelemetry (BEAT) Tops Q3 EPS by 21c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BEAT Hot Sheet
Join SI Premium – FREE
BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.53, $0.21 better than the analyst estimate of $0.32. Revenue for the quarter came in at $100 million versus the consensus estimate of $97.92 million.
GUIDANCE:
BioTelemetry sees FY2018 revenue of $397-400 million, versus the consensus of $394.2 million.
For earnings history and earnings-related data on BioTelemetry (BEAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Upland Software (UPLD) Tops Q3 EPS by 11c ; Offers Guidance
- Cooper-standard Holdings (CPS) Reports Q3 Loss of $0.11, Misses on Revenue; Offers FY26 Revenue Guidance
- Chime Financial, Inc. (CHYM) Tops Q3 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
